Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + binimetinib + pembrolizumab versus nivolumab + ipilimumab in BRAF V600E/K melanoma after anti-PD-1 progression
2021-003640-24Phase 2Active
- Sponsor
- Pfizer
- Start
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of encorafenib, binimetinib, pembrolizumab, nivolumab and ipilimumab in melanoma (2 arms), sponsored by Pfizer. Primary endpoint: ORR. Started Nov 2022; status: active.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2021-003640-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003640-24.